



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/019,510	05/09/2002	Arthur Kammeijer	2799/66496/RDK	8678

7590 06/17/2004

ROBERT D. KATZ
COOPER & DUNHAM, LLP
1185 AVENUE OF THE AMERICAS
NEW YORK, NY 10036

EXAMINER

KWON, BRIAN YONG S

ART UNIT	PAPER NUMBER
----------	--------------

1614

DATE MAILED: 06/17/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/019,510	Applicant(s) KAMMEIJER, ARTHUR	
	Examiner Brian S Kwon	Art Unit 1614	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 6/16/2003.
2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-19 is/are pending in the application.
4a) Of the above claim(s) 1-16 and 19 is/are withdrawn from consideration.
5) ☐ Claim(s) _____ is/are allowed.
6) ☒ Claim(s) 17-18 is/are rejected.
7) ☐ Claim(s) _____ is/are objected to.
8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Applicants Response to Restriction Requirement Acknowledged

1. Applicants' election with the Group E, a method for modulating an immune response of an animal, is acknowledged. Applicants traverse the restriction requirement on the grounds that there would be no burden in searching the entire groups. This argument is not persuasive, as claimed invention would be distinctive, each from the other for the reason of the record.

Furthermore, the search of the entire groups in the non-patent literature (a significant part of a thorough examination) would be burdensome. Therefore, the requirement is still deemed proper, and made Final.

2. It appears that the examiner inadvertently has included claim 19 which is a dependent claim of claim 16, directed to a method for the treatment of oxidative stress of an animal, in Group (E). Accordingly, claims 1-16 and 19 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected claims.

3. Claims 17-18 are currently pending for prosecution on the merits.

Information Disclosure Statement

4. The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609 A(1) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered.

Priority

5. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a))
6. An application in which the benefits of an earlier application are desired should contain a specific reference to the prior application(s) in the first sentence of the specification of in an application data sheet (37 CFR 1.78(a)(2) and (a)(5)).

Specification

7. The specification is objected to because of the following informalities: Throughout the specification, applicant refers to Table 4 (e.g., page 16, line 20; page 17, lines 1-2, 11, 14 and 19; page 18, lines 1, 3 and 11). However, there is no Table 4 in the specification. It appears that applicant failed to include it into the original specification. In case applicant files the amendment to correct the deficiency, applicant is advised not to introduce new matter into the disclosure. 35 U.S.C. 132 states that no amendment shall introduce new matter into the disclosure of the invention.
8. The specification is objected to because of the following informalities: The specification recites in page 19, lines 25-26 that four fractions, designated as R τ 8, R τ 10, R τ 14, R τ 17 are finally selected for identification (peak A, 1-3 in Fig. 4). However, there is insufficient antecedent basis for “R τ 8, R τ 10, R τ 14, R τ 17” and “peak 1-3” in Figure 4. See 37 CFR 1.75(d)(1) and MPEP § 608.01(o).

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

Art Unit: 1614

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

9. Claim 17 is rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a method of reducing contact hypersensitivity with “imidazole-4-carboxylaldehyde, imidazole-4-acetic acid or imidazole-4-carboxylic acid”, does not reasonably provide enablement for a method of modulating an immune response with “an oxidation product of urocanic acid” or “imidazole-4-carboxylaldehyde, imidazole-4-acetic acid or imidazole-4-carboxylic acid”. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims.

The factors to be considered in determining whether a disclosure meets the enablement requirement of 35 U.S.C. 112, first paragraph, have been described in *In re Wands*, 8 USPQ2d 1400 (Fed. Cir. 1988). Among these factors are: (1) the nature of the invention; (2) the state of the prior art; (3) the relative skill of those in the art; (4) the predictability or unpredictability of the art; (5) the breadth of the claims; (6) the amount of direction or guidance presented; (7) the presence or absence of working examples; and (8) the quantity of experimentation necessary. When the above factors are weighed, it is the examiner's position that one skilled in the art could not practice the invention without undue experimentation.

(1) The nature of the invention:

The invention relates to a method of modulating an immune response of an animal with a pharmaceutical composition comprising an oxidation product of urocanic acid.

Art Unit: 1614

(2) The state of the prior art

There are no known compounds of similar structure which have been demonstrated to modulate all types of immune response.

(3) The relative skill of those in the art

The relative skill of those in the art of pharmaceuticals is high.

(4) The predictability or unpredictability of the art

The unpredictability of the pharmaceutical art is very high. Applicant has not provided any competent evidence or disclosed tests that are highly predictive for the pharmaceutical use of the instant compounds. Pharmacological activity in general is a very unpredictable area. Note that in cases involving physiological activity such as the instant case, “the scope of enablement obviously varies inversely with the degree of unpredictability of the factors involved”. See In re fischer, 427 F.2d 833, 839, 166 USPQ 10, 24(CCPA 1970).

(5) The breadth of the claims

The breadth of the claims encompasses the complex systems of a body’s defense reaction against invading substances including a wide range of humoral cell (B-cells) response and cell-mediated immune response (T-cells), wherein said responses are stimulated, inhibited, partially stimulated or partially inhibited by the administration of the claimed compounds.

The broad scope of the instant invention is further exacerbated by the instantly claimed “an oxidation product of urocanic acid”. The breadth of the instant “an oxidation product of urocanic acid” encompasses imidazole-4-carboxyaldehyde (ImCHO), imidazole-4-acetic acid (ImAc), imidazole-4-carboxylic acid (ImCOOH), glyoxylic acid, oxalic acid, CO₂ and other imidazolic UCA oxidation products (unidentified peaks in HPLC analysis).

Art Unit: 1614

(6) The amount of direction or guidance presented or (7) The presence or absence of working examples

The instant specification discloses that the invention provides use of a pharmaceutical composition comprising an oxidation product of urocanic acid for modulating immune responses against various stimuli, thereby mimicking a, previously unknown, natural action of said product (page 4, lines 13-20). The specification also discloses imidazole-4-carboxyaldehyde (ImCHO), imidazole-4-acetic acid (ImAc), imidazole-4-carboxylic acid (ImCOOH), glyoxylic acid and oxalic acid as examples of oxidation product of urocanic acid (UCA). To test the claimed activity of the oxidation product of urocanic acid, the specification discloses the inhibitory effect of the UCA oxidation products in reducing the ear swelling (Fig. 5). The study (Fig. 5) shows that the imidazoles alone only a moderate effect was observed, however, when tested mixed together, the largest reduction was observed. The study also shows that the glyoxylic acid and oxalic acid did not exhibit significant inhibition of contact hypersensitivity.

As discussed above, the specification fails to show that all of the claimed "oxidation product of urocanic acid" would behave similarly. Clearly, the skill artisan would have expected in reading the instant specification (especially page 19, lines 1-16) that the full scope of "oxidation product of urocanic acid" are capable of accomplishing the desired result of the claimed invention.

As discussed above, although specification discloses the inhibitory effects of the UCA oxidation products in reducing the ear swelling, however, the skill artisan would have not arrived at the conclusion of the claimed utility in modulating immune response. There is no demonstrated correlation that tests and results apply to the claimed conditions.

Art Unit: 1614

(8) The quantity of experimentation necessary

The quantity of experimentation needed to be performed by one skilled in the art is yet another factor involved in the determining whether “undue experimentation” is required to make and use the instant invention. “the test is not merely quantitative, since a considerable amount of experimentation is permissible, if it is merely routine, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which the experimentation should proceed.” In re Wands, 858 F.2d 737, 8 USPQ2d 1404 (citing In re Angstadt, 537 F.2d 489, 502-04, 190 USPQ 214, 218 (CCPA 1976)). For these reasons, one of ordinary skill in the art would be burdened with undue “painstaking experimentation study” to determine all of “oxidation product of urocanic acid” and “modulating immune response” that would enabled in this specification.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

10. Claim 17 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Regarding claim 17, the phrase “such as” renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d).

A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) is considered indefinite, since the resulting claim

Art Unit: 1614

does not clearly set forth the metes and bounds of the patent protection desired. Note the explanation given by the Board of Patent Appeals and Interferences in *Ex parte Wu*, 10 USPQ2d 2031, 2033 (Bd. Pat. App. & Inter. 1989), as to where broad language is followed by "such as" and then narrow language. The Board stated that this can render a claim indefinite by raising a question or doubt as to whether the feature introduced by such language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Note also, for example, the decisions of *Ex parte Steigewald*, 131 USPQ 74 (Bd. App. 1961); *Ex parte Hall*, 83 USPQ 38 (Bd. App. 1948); and *Ex parte Hasche*, 86 USPQ 481 (Bd. App. 1949). In the present instance, claim 17 recites the broad recitation "an imidazole", and the claim also recites "imidazole-4-carboxyaldehyde, imidazole-4-acetic acid or imidazole-4-carboxylic acid" which is the narrower statement of the range/limitation.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an

Art Unit: 1614

international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

11. Claim 18 is rejected under 35 U.S.C. 102(b) as being anticipated by Roberts et al. (US 3515789).

Roberts teaches use of imidazole-4-acetic acid (imidazoleacetic acid) for inducing analgesia in a warm-blooded animal (column 1, lines 15-23; column 2, lines 23-54; claims).

Although the reference is silent about the activity of imidazole-4-acetic acid in modulating an immune response of an animal, such property or characteristic must be inherently presented in the referenced method. Since the administration of the same compound to the same population group (recipient) would inherently possess the claimed therapeutic utility, therefore, the reference anticipates the claimed invention even absent explicit recitations of the mechanism of action.

12. Claim 17 is rejected under 35 U.S.C. 102(e) as being anticipated by Hart (US 6133318).

Hart teaches the use of oxalic acid or composition comprising oxalic acid for treating viral diseases such as HIV, SLE, AIDS, lessening or controlling of the destruction of the body's immune system or improving or boosting immune system (abstract; column 5, lines 48-61; column 34, lines 55-51; column 35, line 39 thru column 36, line 32).

Conclusion

13. No Claim is allowed.

Art Unit: 1614

14. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Kwon whose telephone number is (571) 272-0581. The examiner can normally be reached Tuesday through Friday from 9:00 am to 7:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel, can be reached on (571) 273-0584. The fax number for this Group is (703) 872-9306.

Any inquiry of a general nature of relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Brian Kwon
Patent Examiner
AU 1614

A handwritten signature in black ink, appearing to be 'B. Kwon', followed by a long horizontal line extending to the right.